AGM/EGMMay 21, 2026, 04:18 PM
ANI Pharmaceuticals Stockholders Approve 2022 Stock Plan, Elect Directors
AI Summary
ANI Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders where several key proposals were approved. Stockholders elected all seven director nominees and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026. Additionally, the Company's Amended and Restated 2022 Stock Incentive Plan was approved, along with the compensation of named executive officers on an advisory basis. Stockholders also voted for future advisory votes on executive compensation to be held annually.
Key Highlights
- Stockholders approved the Amended and Restated 2022 Stock Incentive Plan with 13,806,050 votes.
- All seven director nominees were elected to serve until the 2027 Annual Meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026.
- The compensation of named executive officers was approved on an advisory basis with 13,819,988 votes.
- Stockholders voted for future advisory votes on executive compensation to be held every one year.
- A total of 22,761,062 votes were entitled to be cast, with 16,926,047 votes present, forming a quorum.
Price Impact
More from ANIP